P2 to dial in cardioprotection and support anticancer validation. P3 confirmatory study still required. But long way off let’s get Ethics and P1 safety and P1B CPaCS insights.
Shareholders getting older by the day, may need anti-aging protection!
http://onbiostatistics.blogspot.com/2016/12/control-for-type-i-error-or-adjustment.html?m=1
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.20 |
Change
0.015(1.27%) |
Mkt cap ! $208.4M | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.20 | $1.17 | $139.7K | 118.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 666 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.20 | 7691 | 3 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| RAC (ASX) Chart |